Tag Archive for: Appointment

Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer

/in

Vicore continues to strengthen its leadership in idiopathic pulmonary fibrosis (IPF) drug development by appointing Dr. Lindmark as its new Chief Medical Officer Lindmark brings deep expertise in late-stage clinical development for respiratory diseases, having developed Symbicort and several other global respiratory brands Appointment reflects Vicore’s advancement to late-stage development in IPF, following the interim […]

Read more

Versameb AG Names Dr. Alexandre LeBeaut as Chair of the Board of Directors

/in

Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately. Dr. LeBeaut has over two decades of global R&D leadership experiences, successfully bringing multiple medicines to […]

Read more

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus

/in

Paris, France, 28 November, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Michel Spagnol as its new Chairman of the Board. Michel joins existing Board members Jérémie Laurent, CEO; Alain Huriez, Director; AdBio Partners; Christian […]

Read more

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

/in

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune modulating cancer vaccines based on its T-win® technology platform, announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will […]

Read more

Poolbeg Pharma plc – Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma

/in

Poolbeg team boosted by highly experienced executives with track record of success 9 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. Read more…

Read more
© Optimum Strategic Communications.